CKLS118 / CK Life Sci, Sequencio Therapeutics - LARVOL DELTA

CK Life Sciences Files Patent Applications for Circular mRNA TROP2 Cancer Vaccine (ACCESSWIRE) - "CK Life Sciences...announces the latest progress in its pharmaceutical R&D, namely the filing of an Original Grant Patent application in Hong Kong and a provisional patent application in the United States for novel cancer vaccines targeting Trophoblast Cell Surface Antigen 2 ('TROP2')....TROP2 cancer vaccines covered by the patent application include innovative circular mRNA (circRNA) and fusion protein vaccine constructs that can induce robust T cell immune responses and have demonstrated impressive tumor growth inhibition in preclinical studies of triple-negative breast cancer and colorectal cancer. The results of animal studies involving triple-negative breast cancer ('TNBC') have been encouraging, with mouse models showing 100% tumor growth inhibition after receiving the TROP2 cancer vaccine....Data on the TROP2 cancer vaccines will be presented at upcoming cancer conferences."

Patent • Preclinical • Colorectal Cancer • Triple Negative Breast Cancer